These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34547980)

  • 21. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M
    Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
    Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V
    Sci Rep; 2019 Nov; 9(1):16680. PubMed ID: 31723222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
    Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is ITP a thrombophilic disorder?
    Rodeghiero F
    Am J Hematol; 2016 Jan; 91(1):39-45. PubMed ID: 26547507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura.
    Bal G; Fabian D; Maia D; Ringel F; Salama A
    Ann Hematol; 2017 Dec; 96(12):2045-2056. PubMed ID: 28965224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
    Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
    Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
    Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
    Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.